Ampio Pharmaceuticals (AMPE) AI Stock Analysis

• Market Cap: $3.41K
• Dividend Yield: N/A
• Average Volume (3M): 791.00
• Price to Earnings (P/E): ―
• Beta (1Y): -14.40
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 6
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): -11.09
• Shares Outstanding: 1,135,358
• 10 Day Avg. Volume: 74
• 30 Day Avg. Volume: 791
• PEG Ratio: >-0.01
• Price to Book (P/B): <0.01
• Price to Sales (P/S): 0.00
• P/FCF Ratio: >-0.01
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 27 Underperform
• Price Target: ―

Ampio Pharmaceuticals faces significant financial challenges with zero revenues and ongoing losses. The absence of technical indicators, poor valuation metrics, and lack of earnings call insights further contribute to a low overall stock score.

Ampio Pharmaceuticals Business Overview & Revenue Model

Company Description

Ampio Pharmaceuticals, Inc. (AMPE) is a biopharmaceutical company specializing in the development of therapies for prevalent inflammatory conditions. The company focuses on advancing its lead product candidate, Ampion, which is an anti-inflammatory biologic designed to treat osteoarthritis of the knee, among other inflammatory diseases. Ampio Pharmaceuticals is headquartered in Englewood, Colorado, and operates within the pharmaceutical sector, targeting unmet medical needs with innovative treatment approaches.

How the Company Makes Money

Ampio Pharmaceuticals generates revenue primarily through the development and commercialization of its proprietary drug candidates. The company's earnings are largely dependent on the successful clinical development, regulatory approval, and subsequent market entry of its lead product, Ampion. Revenue streams may include licensing agreements, partnerships with other pharmaceutical companies, or eventual product sales if Ampion receives approval. As a development-stage company, Ampio also relies on funding from investors, grants, or collaborations to support its research and development activities and operational expenses. Significant partnerships or collaborations could enhance its financial standing and facilitate access to broader markets.

Ampio Pharmaceuticals Financial Statement Overview

Summary

Ampio Pharmaceuticals exhibits severe financial difficulties with zero revenue, ongoing losses, declining equity, and negative cash flow, indicating critical financial distress.

Income Statement

Ampio Pharmaceuticals has consistently reported zero revenue over the last five years, indicating a lack of income generation. The company has faced significant operating losses, as reflected by negative EBIT and net income figures, leading to negative profit margins. This suggests ongoing financial struggles with profitability.

Balance Sheet

The balance sheet shows a decreasing trend in stockholders' equity and total assets over the years, which could indicate financial instability. The debt-to-equity ratio is relatively low, suggesting low leverage, but the decreasing equity raises concerns. The company has maintained a positive equity ratio, indicating some level of asset stability despite financial challenges.

Cash Flow

Ampio Pharmaceuticals has experienced negative operating and free cash flows, indicating insufficient cash generation from operations. This trend has persisted over the years, with no significant improvement in cash flow metrics. The lack of positive cash flow poses a risk to the company's ability to finance its operations and potential growth.

Breakdown
Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00
	Gross Profit
-250.00K	-2.08M	-1.09M	-1.18M	-1.27M
	EBIT
-9.52M	-24.21M	-25.16M	-15.22M	-23.45M
	EBITDA
0.00	-18.30M	0.00	0.00	-17.30M
	Net Income Common Stockholders
-8.63M	-8.47M	-12.48M	-16.50M	-8.68M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
4.09M	12.65M	33.89M	17.35M	6.53M
	Total Assets
5.74M	13.59M	38.83M	22.88M	14.00M
	Total Debt
274.00K	614.00K	925.00K	1.21M	1.47M
	Net Debt
-3.81M	-12.04M	-32.97M	-16.14M	-5.06M
	Total Liabilities
2.38M	1.80M	11.54M	5.37M	7.56M
	Stockholders Equity
3.36M	11.79M	27.28M	17.51M	6.44M
Cash Flow		Free Cash Flow
-8.56M	-21.13M	-14.19M	-14.79M	-15.40M
	Operating Cash Flow
-8.56M	-21.13M	-14.09M	-14.73M	-15.38M
	Investing Cash Flow
0.00	0.00	-97.00K	-63.00K	-22.00K
	Financing Cash Flow
0.00	-111.00	30.73M	25.61M	14.35K

Ampio Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
OCGN	60 Neutral	$271.82M	―	-248.97%	―	86.63%	22.29%
Sector *	53 Neutral	$5.14B	3.03	-44.09%	2.83%	16.75%	-0.06%
IBIO	42 Neutral	$13.51M	―	-90.83%	―	650.00%	89.72%
CTXR	38 Underperform	$7.23M	―	-60.06%	―	―	8.99%
ATOS	36 Underperform	$107.43M	―	-34.87%	―	―	15.09%
AMPE	27 Underperform	$3.41K	―	-256.90%	―	―	―